Innovative Therapies and Corneal Transparency (TITC)
Our team works at the convergence of biotechnology, regenerative medicine, and artificial intelligence to offer innovative, personalized, and sustainable solutions for patients with corneal diseases.
Presentation
Our team is committed to developing a portfolio of innovative projects aimed at improving the treatment of corneal opacities, a major cause of visual impairment worldwide. Drawing on a multidisciplinary approach and a strong collaborative dynamic, we develop multi-partner research projects involving academic and clinical institutions.
At the same time, our team is exploring applications of artificial intelligence (AI) to improve the diagnosis and monitoring of corneal diseases, particularly through the analysis of medical images and the use of clinical data.
Close ties with the Quinze-Vingts National Hospital give our research strong clinical reality and accelerate the transfer of innovations into medical practice.
Research areas
Cell therapy: development of treatments based on corneal stem cells to restore corneal tissue function in patients suffering from degenerative diseases.
Tissue therapy: design and evaluation of bioengineered corneal tissue substitutes capable of replacing or regenerating damaged corneal tissue.
Corneal organoids: advanced modeling of the human cornea in vitro using organoids, for a better understanding of pathophysiological mechanisms and for therapeutic screening.
Modeling corneal diseases: studying and reproducing pathologies such as Fuchs' dystrophy, keratoconus, and aniridia in the laboratory in order to better understand their evolution and to develop targeted therapeutic approaches.
Team members
Scientific publications
Below you will find the latest scientific publications in this field: Innovative Therapies and Corneal Transparency (TITC).